User:Mr. Ibrahem/Sulbactam/durlobactam

Sulbactam/durlobactam, sold under the brand name Xacduro, is a co-packaged medication used to treat bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex. It is given by injection into a vein over 3 hours. The other primary treatment for this condition is colistin.

Common side effects include liver problems, low red blood cells, diarrhea, and low potassium. Other side effects may include allergic reactions and Clostridioides difficile-associated diarrhea. It contains sulbactam, a beta-lactam antibacterial and beta-lactamase inhibitor; and durlobactam, a beta-lactamase inhibitor.

Sulbactam/durlobactam was approved for medical use in the United States in 2023. It was not currently available commercially as of August 2023, but was expected to become available in later 2023 in the United States.